Keyword: European Commission

After months of regulatory scrutiny, the EU has given AbbVie and Allergan's $63 billion merger its first go-ahead in anticipation of an FTC decision.

We may be focusing on our forecasts for the year ahead with today's issue, but here's some Friday news we thought you shouldn't miss.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Roche’s Tecentriq is on a roll in Europe. After picking up a green light in breast cancer last week, it's now snagged a pair of go-aheads in lung cancer.

In March, Roche’s Tecentriq led its class into the triple-negative breast cancer arena with an FDA nod. Now, it’s done the same across the pond.

Sanofi and Regeneron’s Libtayo is two for two in the last two days—at winning over key European regulatory and reimbursement bodies, that is.

The new endorsement of Celgene's Revlimid from England's cost watchdog NICE may not help calm fears about BMS' $74 billion buyout.

Stymied by an FDA rejection last year, Ionis and Akcea’s Waylivra seemed doomed. Fortunately, the ultrarare disease drug found new life in Europe.

After a tough year in the competitive MS field, Sanofi’s Lemtrada could hardly afford another setback. But that’s exactly what it got.

The EU approval is conditional on selling off a Shire experimental IBD drug, which Takeda said could attract "a number of potential buyers."